Novel Early Pregnancy Multimarker Screening Test for Preeclampsia Risk Prediction

Preeclampsia (PE) is a common pregnancy-linked disease, causing preterm births, complicated deliveries, and health consequences for mothers and offspring. We have previously developed 6PLEX, a multiplex assay that measures PE-related maternal serum biomarkers ADAM12, sENG, leptin, PlGF, sFlt-1, and PTX3 in a single test tube. This study investigated the potential of 6PLEX to develop novel PE prediction models for early pregnancy. We analyzed 132 serum samples drawn at 70–275 gestational days (g days) from 53 pregnant women (PE, n = 22; controls, n = 31). PE prediction models were developed using a machine learning strategy based on the stepwise selection of the most significant models and incorporating parameters with optimal resampling. Alternative models included also placental FLT1 rs4769613 T/C genotypes, a high-confidence risk factor for PE. The best performing PE prediction model using samples collected at 70–98 g days comprised of PTX3, sFlt-1, and ADAM12, the subject's parity and gestational age at sampling (AUC 0.94 [95%CI 0.84–0.99]). All cases, that developed PE several months later (onset 257.4 ± 15.2 g days), were correctly identified. The model's specificity was 80% [95%CI 65–100] and the overall accuracy was 88% [95%CI 73–95]. Incorporating additionally the placental FLT1 rs4769613 T/C genotype data increased the prediction accuracy to 93.5% [AUC = 0.97 (95%CI 0.89–1.00)]. However, 6PLEX measurements of samples collected at 100–182 g days were insufficiently informative to develop reliable PE prediction models for mid-pregnancy (accuracy <75%). In summary, the developed model opens new horizons for first-trimester PE screening, combining the easily standardizable 6PLEX assay with routinely collected antenatal care data and resulting in high sensitivity and specificity.

[1]  F. Jehee,et al.  Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study , 2022, American journal of human genetics.

[2]  L. Sobrevia,et al.  Using Machine Learning to Predict Complications in Pregnancy: A Systematic Review , 2022, Frontiers in Bioengineering and Biotechnology.

[3]  S. Cicero,et al.  Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia , 2021, Circulation.

[4]  K. Devriendt,et al.  Outcome of publicly funded nationwide first-tier noninvasive prenatal screening , 2021, Genetics in Medicine.

[5]  M. Laan,et al.  C-allele of rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor for Preeclampsia , 2020, Hypertension.

[6]  D. Sahota,et al.  First trimester preeclampsia screening and prediction. , 2020, American journal of obstetrics and gynecology.

[7]  Meiyuan Jin,et al.  Association between pentraxin-3 and the risk of preeclampsia , 2020, Medicine.

[8]  M. Laan,et al.  Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. , 2020, The journal of applied laboratory medicine.

[9]  Andrea Montanari,et al.  Early prediction of preeclampsia via machine learning. , 2020, American journal of obstetrics & gynecology MFM.

[10]  H. Stepan,et al.  Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia , 2020, Hypertension.

[11]  L. Raio,et al.  FIRST TRIMESTER SCREENING FOR PREECLAMPSIA – A SYSTEMATIC REVIEW , 2019, Hypertension in pregnancy.

[12]  L. Chappell,et al.  Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. , 2019, BMJ.

[13]  Yejin Park,et al.  Prediction model development of late-onset preeclampsia using machine learning-based methods , 2019, PloS one.

[14]  A. Staff The two-stage placental model of preeclampsia: An update. , 2019, Journal of reproductive immunology.

[15]  K. Nicolaides,et al.  The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  Yanming Feng,et al.  Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA , 2019, Nature Medicine.

[17]  A. Papageorghiou,et al.  ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[18]  L. Magee,et al.  The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. , 2018, Pregnancy hypertension.

[19]  Nicola Persico,et al.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.

[20]  D. Lawlor,et al.  Variants in the fetal genome near FLT1 are associated with risk of preeclampsia , 2017 .

[21]  S. Cicero,et al.  Accuracy of competing‐risks model in screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[22]  L. Sentilhes,et al.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. , 2017, New England Journal of Medicine.

[23]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[24]  D. Wright,et al.  Competing risks model in screening for preeclampsia by maternal characteristics and medical history. , 2015, American journal of obstetrics and gynecology.

[25]  L. Magee,et al.  The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. , 2014, Pregnancy hypertension.

[26]  I. Sargent,et al.  IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? , 2014, Placenta.

[27]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[28]  R. Hoover,et al.  Maternal angiogenic profile in pregnancies that remain normotensive. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[29]  H. Stepan,et al.  Relation Between Maternal Angiogenic Factors and Utero-Placental Resistance in Normal First- and Second-Trimester Pregnancies , 2011, Hypertension in pregnancy.

[30]  François Audibert,et al.  Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.

[31]  George G Klee,et al.  Antibody-based protein multiplex platforms: technical and operational challenges. , 2010, Clinical chemistry.

[32]  A. Papageorghiou,et al.  First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction , 2009, Acta obstetricia et gynecologica Scandinavica.

[33]  F. Schmidt Meta-Analysis , 2008 .

[34]  K. Johnson An Update. , 1984, Journal of food protection.